|View printer-friendly version|
|St. Jude Medical Announces FDA Clearance of the AMPLATZER Vascular Plug 4|
Device allows physicians to reroute blood flow by blocking abnormal vessels
As the industry’s first vascular plug that can be delivered using a standard diagnostic catheter, the AVP 4 offers physicians the ability to treat smaller and more difficult-to-access blood vessels using vascular plug technology. The AVP 4 also provides full cross-sectional vessel coverage and may be recaptured and repositioned prior to deployment, allowing physicians to block a vessel with greater precision and speed than is achievable with conventional embolic coils.
“The AMPLATZER Vascular Plugs have been beneficial in precisely
targeting specific vessels for embolization,” said Dr.
Vascular plugs assist physicians in quickly blocking or rerouting blood flow by occluding (closing) abnormal blood vessels. Vascular occlusion lessens pressure on malformed, weakened or leaking blood vessels and reduces blood supply to benign or malignant tumors. The current standard of care for vascular occlusion involves placing several individually threaded coils through a catheter and packing them together to block blood flow.
“Approval of the AVP 4 represents a significant milestone for our U.S.
vascular business,” said
The AMPLATZER Vascular Plug 4 received European CE Mark approval in
About the AMPLATZER Family of Vascular Plugs
AVP 4 is the latest addition to the AMPLATZER Family of Vascular Plugs, which includes the AVP and AVP II devices in the U.S. The AMPLATZER Family of Vascular Plugs are designed to provide optimal embolization of peripheral arteries and veins through single-device occlusion; full cross-sectional vessel coverage; and controlled, precise deployment. A single device from the AMPLATZER Family of Vascular Plug embolizes a vessel that would often require many coils, which makes it an efficient and cost-effective alternative.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the